

## REMARKS

The claims are 1 to 4.

The above amendment is responsive to points set forth in the Official Action.

With regard to the rejection under 35 U.S.C. 112, the claims have been amended to recite 8 wt% as the upper limit of the pyrimidine compound, per the Examiner's comments.

Further, claim 1 now recites that the pyrimidine ring is optionally substituted with amino per the Examiner's suggestion.

A Claim of Priority accompanies.

Submitted herewith is an IDS enclosing copies of the references discussed at page 2 of the Specification.

Favorable action is now requested.

Respectfully submitted,

Kiyokazu SHUKU et al.

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

By: Matthew M. Jacob  
Matthew M. Jacob  
Registration No. 25,154  
Attorney for Applicants

MJ/kes  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
November 1, 2005